Publications by authors named "Delphine Staumont Salle"
Background: Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample-size and/or follow-up duration are available.
Methods: The COHESion study is a national prospective multicenter multidisciplinary cohort recruiting both adults or children with the spectrum of eosinophilic disorders (including reactive HE/HES [HE/HES-R], idiopathic HES [HES-I], lymphocytic HES [HES-L], neoplastic HE/HES [HE/HES-N], HE of unknown significance [HE-US], as well as IgG4-related disease [IgG4RD] or ANCA-negative eosinophilic granulomatosis with polyangiitis [EGPA] overlaps).
Background: Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR).
Objective: To evaluate DOAE and DFR outcomes after switching to tralokinumab or Janus kinase inhibitor (JAKi).
Methods: This retrospective study included 106 patients discontinuing dupilumab because of DOAEs and/or DFR.
Article Synopsis
- Octylisothiazolinone (OIT) is a biocide used in leather products, raising concerns about allergic reactions, particularly in headphones.
- A study reported cases of allergic contact dermatitis (ACD) in patients linked to headphones containing OIT, confirming its strong allergic potential through patch testing and chemical analysis.
- The findings suggest that OIT is a significant sensitizer and highlight the need for safer use guidelines and improved product labeling in the leather industry to protect consumers.
In patients with moderate to severe atopic dermatitis (AD) showing an inadequate response to dupilumab 300mg/2weeks, few real-life studies reported the response to alternative regimen maintaining dupilumab. To assess and analyze the response to an increased dose of dupilumab or its combination with cyclosporin A (CsA), methotrexate (MTX), or itraconazole (ITRA), all adult AD patients from 7 French University Hospitals were retrospectively included if they achieved an inadequate response to dupilumab 300mg/2weeks and were subsequently treated with an increased dose of dupilumab (300mg every 7 or 10 days), or a combination of dupilumab 300mg/2weeks with CsA, MTX or ITRA. The response after 3 months, along with epidemiological, clinical, and therapeutic baseline characteristics, were collected.
View Article and Find Full Text PDFBackground: Bidirectional interactions between eosinophils and mast cells (MCs) have been reported in various allergic diseases. Bone marrow (BM) eosinophilia, and to a lesser extent blood eosinophilia, is common in systemic mastocytosis (SM), but its significance remains unknown.
Objective: We described blood and BM eosinophil characteristics in SM.
Article Synopsis
- Pseudoxanthoma elasticum is a genetic disease that causes abnormal mineralization in the skin, eyes, and blood vessels, leading to various symptoms.
- The condition is characterized by small yellow or skin-colored bumps, primarily on the neck and in areas like the armpits and around the belly button, along with loose and wrinkled skin.
- Diagnosing this condition can be challenging, especially in individuals with darker skin tones, and dermatologists often refer patients to specialists for further evaluation of potential complications.
Article Synopsis
- * Out of 153 patients, 20% needed a dose increase after 3 months, and this rose to 27% by 9 months, primarily by increasing injection frequency rather than dosage.
- * Patients requiring updosing were typically those with more severe CSU symptoms and lower IgE levels, but side effects did not increase as a result of higher dosing.
Article Synopsis
- Atopic dermatitis (AD) is a skin condition that can be difficult to treat in certain body areas; this study focused on how lebrikizumab impacts AD severity across different regions.
- In two clinical trials, lebrikizumab was administered every two weeks, and patients showed significant improvement in the Eczema Area and Severity Index (EASI) after 16 weeks compared to those given a placebo.
- Results indicated that lebrikizumab led to rapid improvements in AD symptoms, with significant advancements observable as early as week 2, particularly benefiting all body regions and clinical signs measured.
Background: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD.
Methods: Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long-term extension ECZTEND (NCT03587805) trials.
Importance: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment.
Objective: To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS.
Article Synopsis
- * In a study using a mouse model, IVIg was found to effectively prevent skin inflammation and fibrosis by decreasing immune cell infiltration and lowering levels of specific proinflammatory cytokines and fibrosis markers.
- * While IVIg could reduce skin and dermal thickness when given as treatment, its effects on skin inflammation and established fibrosis were less clear, suggesting that more research is needed to explore the timing and frequency of IVIg administration in SSc patients.
Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study.
J Allergy Clin Immunol Pract
December 2023
Background: Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU).
Objective: We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU.
Methods: We conducted a retrospective multicenter study in 9 French tertiary referral hospitals.
Article Synopsis
- Sleep disorders, particularly excessive daytime sleepiness, are prevalent in patients with atopic dermatitis, affecting 46.1% of those studied.
- This daytime sleepiness is linked to the severity of atopic dermatitis and negatively impacts patients' quality of life and overall well-being.
- The findings highlight the need for assessing and managing sleep issues in these patients, suggesting that targeted intervention programs could enhance their quality of life.
Article Synopsis
- - Atopic dermatitis is a chronic skin condition that affects not only the patients but also their partners, yet its impact on partners has been under-explored.
- - A study involving 1,266 patient-partner pairs revealed that the severity of atopic dermatitis correlates with higher burden scores for both patients and their partners, with significant differences in burden levels among mild, moderate, and severe cases.
- - The research indicated that both patients and their partners experience impaired sleep quality, and the condition negatively affects sexual desire, reported by 39% of partners and 26% of patients.
Background: Systemic treatment options for psoriasis are limited for patients with recent neoplasia.
Objectives: We report the real-life use of apremilast (APR) in patients with psoriasis and recent cancer.
Materials & Methods: We conducted a retrospective, multicentre study in five hospitals and among 120 private dermatologists in the north of France from January 2015 to May 2021.
Eosinophilic-related clinical manifestations are protean and the underlying conditions underpinning eosinophilia are highly diverse. The etiological workup of unexplained eosinophilia/hypereosinophilia can be challenging, and can lead sometimes to extensive, inappropriate, costly and/or invasive investigations. To date, guidelines for the etiological workup and management of eosinophilia are mainly issued by hematologists, and thus mostly cover the scope of clonal hypereosinophilic syndromes (HES).
View Article and Find Full Text PDF